Transamerica Financial Advisors LLC Lowers Stake in Vertex Pharmaceuticals Incorporated $VRTX

Transamerica Financial Advisors LLC lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 1.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,851 shares of the pharmaceutical company’s stock after selling 101 shares during the quarter. Transamerica Financial Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $3,807,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in VRTX. Quent Capital LLC boosted its position in Vertex Pharmaceuticals by 4.5% during the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company’s stock valued at $249,000 after purchasing an additional 22 shares in the last quarter. Advisor OS LLC boosted its holdings in shares of Vertex Pharmaceuticals by 4.4% in the 1st quarter. Advisor OS LLC now owns 543 shares of the pharmaceutical company’s stock valued at $263,000 after buying an additional 23 shares in the last quarter. Sculati Wealth Management LLC grew its position in shares of Vertex Pharmaceuticals by 1.0% in the 4th quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company’s stock worth $1,029,000 after buying an additional 25 shares during the last quarter. Avidian Wealth Enterprises LLC grew its position in shares of Vertex Pharmaceuticals by 2.1% in the 1st quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company’s stock worth $594,000 after buying an additional 25 shares during the last quarter. Finally, Strategic Blueprint LLC raised its stake in shares of Vertex Pharmaceuticals by 1.7% during the 1st quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company’s stock worth $726,000 after acquiring an additional 25 shares in the last quarter. 90.96% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on VRTX shares. Morgan Stanley set a $439.00 price target on shares of Vertex Pharmaceuticals and gave the stock an “equal weight” rating in a report on Tuesday, August 5th. William Blair reissued an “outperform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. JPMorgan Chase & Co. boosted their target price on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an “overweight” rating in a research note on Monday, July 14th. HC Wainwright reduced their target price on Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research report on Tuesday, August 5th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and thirteen have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $497.10.

Get Our Latest Stock Report on VRTX

Insider Activity

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This trade represents a 12.50% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.20% of the stock is currently owned by company insiders.

Vertex Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ:VRTX opened at $387.18 on Wednesday. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $519.88. The stock has a market cap of $99.27 billion, a price-to-earnings ratio of 27.68 and a beta of 0.44. The business has a 50-day moving average price of $436.66 and a 200-day moving average price of $460.13.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last issued its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, topping the consensus estimate of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The company had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. During the same quarter in the prior year, the company earned ($12.83) EPS. Vertex Pharmaceuticals’s quarterly revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Further Reading

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.